Formulated PSTA Injection Versus PATA Alone in the Management of Macular Edema Secondary to Non-ischemic Retinal Vein Occlusions
Formulated Posterior Subtenon Triamcinolone (PSTA) Injection Versus Posterior Subtenon Triamcinolone Alone in the Management of Macular Edema Secondary to Non-ischemic Retinal Vein Occlusions
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New Damietta
-
Damieta, New Damietta, Egypt, 34517
- Ehab tharwat
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diminution vision due to macular edema secondary to non-ischemic retinal vein occlusions, either central or branch, as evidenced by clinical and angiographic evaluation
- CMT ≥ 250 µ.
- Willing to participate in the study
Exclusion Criteria:
- Unwilling to participate in the study.
- Ischemic RVO
- Prior laser treatment
- Glaucoma/Ocular Hypertension
- Cataract which lead to difficulty in the evaluation of macula
- Vitreous hemorrhage
- Macular ischemia
- Iris neovascularisation
- patients with intravitreal injection of anti VEGFs, steroid, or any intraocular surgery 3 months prior to the inclusion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Formulated Posterior Sub Tenon Triamcinolone
|
formulated with sodium hyaluronate and chondroitin sulfate
|
|
Active Comparator: Posterior Sub Tenon Triamcinolone alone
|
Triamcinolone Acetonide alone
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Best-corrected visual acuity (BCVA)
Time Frame: Baseline
|
will be measured with the Snellen chart
|
Baseline
|
|
Best-corrected visual acuity (BCVA)
Time Frame: at 1st month
|
will be measured with the Snellen chart
|
at 1st month
|
|
Best-corrected visual acuity (BCVA)
Time Frame: at 3rd month
|
will be measured with the Snellen chart
|
at 3rd month
|
|
Best-corrected visual acuity (BCVA)
Time Frame: at 6th month
|
will be measured with the Snellen chart
|
at 6th month
|
|
central macular thickness ( CMT)
Time Frame: at baseline
|
CMT will be measured with OCT
|
at baseline
|
|
central macular thickness ( CMT)
Time Frame: at 1st month
|
CMT will be measured with OCT
|
at 1st month
|
|
central macular thickness ( CMT)
Time Frame: at 3rd month
|
CMT will be measured with OCT
|
at 3rd month
|
|
central macular thickness ( CMT)
Time Frame: at 6th month
|
CMT will be measured with OCT
|
at 6th month
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Eye Diseases
- Retinal Degeneration
- Retinal Diseases
- Embolism and Thrombosis
- Venous Thrombosis
- Thrombosis
- Macular Degeneration
- Macular Edema
- Retinal Vein Occlusion
- Edema
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Immunosuppressive Agents
- Immunologic Factors
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Protective Agents
- Adjuvants, Immunologic
- Viscosupplements
- Triamcinolone
- Triamcinolone Acetonide
- Triamcinolone hexacetonide
- Triamcinolone diacetate
- Hyaluronic Acid
Other Study ID Numbers
Other Study ID Numbers
- PSTA and macular edema
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.